Home
Articles I
Alcohol
Amphetamines
Anabolics, steroids & doping
Benzodiazepines
Cannabis, marijuana & haschisch
Cocaine, coca, crack & base
Khat
Opiates & methadone
Party drugs, dance drugs & clubbing
Psychedelics
Tobacco
Articles II
Addiction
Crime, police & trafficking
Demand reduction
Economics
Eduction & prevention
Gender issues
HIV/AIDS & HCV
International & National Drug Policy
Law & Treaties
Minorities
Needle exchange & user rooms
Overdose
Prison & probation
Self help, peer support & outreach
Self regulation & controlled use
Sex work, sex and prostitution
Supply reduction
Testing
Treatment
Various general
Various research
Work & work place
Youngsters and adolescents
Books
CLICK HERE FOR A FULL LIST OF ALL BOOKS
Law
Single Convention, 1961
Single Convention Commentary
Single Convention Protocol Commentary
Vienna Convention 1971
Vienna Convention 1988
Vienna Convention Law of Treaties
Protocol Political & Civil Rights
Precedent (jurisprudence)
European Council
European Parliament
Manuals
Methadone Briefing
Peer Support Manual
Rate Your Risks
Risk reduction in prison
Methadone Handbook
Safer Injecting Briefing
EMCDDA Cannabis Reader
Reports
CLICK HERE FOR A FULL LIST OF ALL REPORTS
Grey Literature
User Organisations and Advocacy Groups
Press
New
Abuse-Drug.com
Main Menu
Search Drugtext
Home
Articles
Books
Law & Treaties
Manuals
Reports
Press
Sitemap
Drugtext Feeds
Psychopharmacology
Introduction
Pharmacology
Psychopharmacology
Nervous system I
Nervous system II
Neurotransmitters
Overdose
Addiction
Substances
59.4%
United States
8.7%
United Kingdom
5%
Canada
4%
Australia
3.5%
Philippines
2.6%
Netherlands
2.4%
India
1.6%
Germany
1%
France
0.7%
Poland
Today:
159
Yesterday:
251
This Week:
159
Last Week:
2221
This Month:
4747
Last Month:
6796
Total:
129346
Contents
Saturday, 16 January 2010 00:00 |
Written by Andrew Preston |
|
|
Drug Abuse
Foreword
Section 1
The history of methadone and methadone prescribing
Section 2
The research basis for methadone prescribing
Section 3
Methadone manufacture and the preparations available
Section 4
Physiology and pharmacology of methadone
Section 5
Methadone and the law
Section 6
Assessment
Section 7
Treatment aims and treatment choices
Section 8
Getting the starting dose right
Section 9
Methadone detoxification
Section 10
Practical issues in methadone prescribing
Section 11
Prescribing for groups with special needs
References
Credits
Note
Important note on long-term detox: reducing doses over 1 month or longer
Last Updated (Thursday, 06 January 2011 17:13)
Show Other Articles Of This Author
Contents
(31 January 2010)
Introduction
(30 January 2010)
The history of methadone
(29 January 2010)
Tolerance
(28 January 2010)
Long-term effects
(27 January 2010)